Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Honda Motor Company Ltd. Common Stock (HMC) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance

Honda Motor Company Ltd. Common StockTrade
Maravai LifeSciences Holdings Inc. Class A Common StockTrade

Price performance (Past 24H)

Key statistics

Honda Motor Company Ltd. Common Stock vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Honda Motor Company Ltd. Common Stock trades at $33.84 (market cap $43.08B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Honda Motor Company Ltd. Common Stock is far larger — about 44.3× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Honda Motor Company Ltd. Common Stock pays a 4% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Honda Motor Company Ltd. Common Stock for 6 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.

HMCMRVI
Market Cap
$43.08B$972.90M
Volume
823,3184,325,710
Sector
Consumer CyclicalHealth
52-Week High
$33.45$9.00
52-Week Low
$23.49$2.83
Typical Hold Time
6 Days0 Days
Enterprise Value
$40.26B$1.08B
Dividend Yield
4%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Honda Motor Company Ltd. Common Stock

Honda Motor Co. (HMC) trades at $33.33, up 2.05% with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with revenue growth to $22.5T in 2026 but negative net income margins, while valuation metrics appear attractive with P/S of 0.32 and EV/EBITDA of 4.92. Recent news highlights strategic investments in hybrid technology and cost-cutting initiatives.

HMC presents a value opportunity with reasonable valuations and positive earnings surprises, though profitability challenges and competitive pressures create headwinds. Analyst consensus leans moderate buy with institutional interest, but investors should weigh cost reduction progress against margin pressures in the evolving auto industry.

Maravai LifeSciences Holdings Inc. Class A Common Stock

Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.

The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HMC

No sentiment data available yet.

MRVI
100% Buy0% Sell
Avg holding period · 0 Days

Top news

Latest headlines on both assets

About Honda Motor Company Ltd. Common Stock

Honda Motor manufactures automobiles, motorcycles, power products, and related financial services. Its brands serve consumer and commercial transportation markets globally.

Read more on HMC →

About Maravai LifeSciences Holdings Inc. Class A Common Stock

Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.

Read more on MRVI →